A Study of GLB-001 in Patients With Myeloid Malignancies

Key facts

Sponsor

Hangzhou GluBio Pharmaceutical Co., Ltd.

Principal Investigator

Gang Lu, Ph.D.

Hangzhou GluBio Pharmaceutical Co., Ltd.

Intervention

GLB-001(drug)

Enrollment

108 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (14)

• The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
• China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• The First Hospital of Hebei Medical Universtiy, Shijiazhuang, Hebei, China
• Henan Cancer Hospital, Zhengzhou, Henan, China
• Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
• The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
• The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• Sheng Jing Hospital of China Medical Universtiy, Shenyang, Liaoning, China
• Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China
• Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
• The Second Hospital of Tianjin Medical Universtiy, Tianjin, Tianjin Municipality, China
• The First Affilicated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
• The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06303193
  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
  National Cancer Institute (NCI)
• RECRUITINGPHASE3NCT07422480
  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Takeda
• RECRUITINGNANCT07500753
  A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE4NCT07486713
  Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
  Rigel Pharmaceuticals
• RECRUITINGPHASE1NCT07107126
  Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
  Remedy Plan, Inc.
• RECRUITINGPHASE1NCT07270978
  Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
  University of Virginia
• RECRUITINGNANCT06781099
  Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Hospices Civils de Lyon
• RECRUITINGPHASE2NCT07228273
  Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
  OHSU Knight Cancer Institute

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →